Who
Jonathan S. Leff
Director
Company insider
Files Form 4 as: Director, Larimar Therapeutics; Director, BiomX; Director, Protara Therapeutics; Director, AveXis; Director, Nivalis Therapeutics; Director, Intermune; Director, Allos Therapeutics; Director, Talon Therapeutics.
In numbers
- Trades disclosed
- 339
- Buys
- 16
- Sells
- 0
- Bought
- $107.3M
- Sold
- $0
- Companies
- 13
- Companies where not an officer
- 13
- First trade
- 31 Jan 2006
- Last trade
- 19 May 2026
- Last filed
- 20 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 19 May 2026filed 20 May 2026 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,150 at $0.00 | filing |
| 19 May 2026filed 20 May 2026 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —55,150 at $0.00 | filing |
| 13 May 2025filed 14 May 2025 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 14 Apr 2025filed 21 Apr 2025 | BiomXoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,600 at $0.00 | filing |
| 14 Apr 2025filed 18 Apr 2025 | BiomXoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,600 at $0.00 | filing |
| 11 Jul 2024filed 15 Jul 2024 | BiomXoption or derivative · Biotechnology | SEC FORM 4 Code A | —264,000 at $0.00 | filing |
| 29 May 2024filed 31 May 2024 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —19,000 at $0.00 | filing |
| 9 May 2023filed 11 May 2023 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,300 at $0.00 | filing |
| 10 May 2022filed 12 May 2022 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,300 at $0.00 | filing |
| 12 May 2021filed 17 May 2021 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,300 at $0.00 | filing |
| 29 Sep 2020filed 30 Sep 2020 | LRMR Larimar Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,600 at $0.00 | filing |
| 8 Jun 2018filed 12 Jun 2018 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,700 at $0.00 | filing |
| 2 Aug 2017filed 4 Aug 2017 | TARA Protara Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,333 at $0.00 | filing |
| 10 Feb 2016filed 12 Feb 2016 | AveXisoption or derivative | SEC FORM 4 Code A | —18,111 at $0.00 | filing |
| 10 Feb 2016filed 12 Feb 2016 | AveXisoption or derivative | SEC FORM 4 Code A | —8,385 at $0.00 | filing |
| 11 Sep 2015filed 15 Sep 2015 | Nivalis Therapeuticsoption or derivative | SEC FORM 4 Code A | —7,650 at $0.00 | filing |
| 16 Jul 2015filed 20 Jul 2015 | Nivalis Therapeuticsoption or derivative | SEC FORM 4 Code A | —11,475 | filing |
| 28 Feb 2013filed 1 Mar 2013 | Intermune | SEC FORM 4 Code F | $62K7,108 at $8.79 | filing |
| 4 Sep 2012filed 5 Sep 2012 | Allos Therapeutics | SEC FORM 4 Code U | $100K55,000 at $1.82 | filing |
| 4 Jun 2012filed 6 Jun 2012 | Intermuneoption or derivative | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.